The Radiation Issue in Cardiology: the time for action is now

The "radiation issue" is the need to consider possible deterministic effects (e.g., skin injuries) and long-term cancer risks due to ionizing radiation in the risk-benefit assessment of diagnostic or therapeutic testing. Although there are currently no data showing that high-dose medical studies have actually increased the incidence of cancer, the "linear-no threshold" model in radioprotection assumes that no safe dose exists; all doses add up in determining cancer risks; and the risk increases linearly with increasing radiation dose. The possibility of deterministic effects should also be considered when skin or lens doses may be over the threshold. Cardiologists have a special mission to avoid unjustified or non-optimized use of radiation, since they are responsible for 45% of the entire cumulative effective dose of 3.0 mSv (similar to the radiological risk of 150 chest x-rays) per head per year to the US population from all medical sources except radiotherapy. In addition, interventional cardiologists have an exposure per head per year two to three times higher than that of radiologists. The most active and experienced interventional cardiologists in high volume cath labs have an annual exposure equivalent to around 5 mSv per head and a professional lifetime attributable to excess cancer risk on the order of magnitude of 1 in 100. Cardiologists are the contemporary radiologists but sometimes imperfectly aware of the radiological dose of the examination they prescribe or practice, which can range from the equivalent of 1-60 mSv around a reference dose average of 10-15 mSv for a percutaneous coronary intervention, a cardiac radiofrequency ablation, a multi-detector coronary angiography, or a myocardial perfusion imaging scintigraphy. A good cardiologist cannot be afraid of life-saving radiation, but must be afraid of radiation unawareness and negligence.

Almost 10 years ago, the "radiation issue" was raised, which refers to the need to include long-term cancer risks due to ionizing radiation in the risk-benefit assessment of diagnostic or therapeutic testing. This issue is obviously relevant from the individual patient's [1], societal [2] and bioethical [3] perspective, and clearly stemmed from standard radioprotection knowledge already at that time well-embedded in Euratom law [4] and European Commission medical imaging guidelines [5]. It was initially raised in the critical area of non-invasive diagnosis of coronary artery disease, where the dose of 10 million stress imaging future procedures per year, the high dose of perfusion imaging and the availability of competitive non-ionizing techniques pose special problems of avoidable long-term cancer risk [1, 6]. However, at that time this position was largely perceived by peers as being motivated by an attempt of non-radiologist imaging specialists to expand or defend their own imaging market shares [7]. In the last 10 years, things have changed. For a long time ignored by the mainstream imaging and cardiology community, the "linear-no threshold" model in radioprotection assumes that no safe dose exists; the risk increases linearly with increasing radiation dose; all doses add up in determining cancer risk. This model was more generally accepted as epidemiological evidence matured, and was re-endorsed by concordant statements of the US National Academy of Sciences Biological Effects of Ionizing Radiation Committee (2006), International Commission on Radiological Protection (2007), and United Nations Scientific Committee on the Effects of Atomic Energy (2008) [8–10]. Conversely, the hormesis model assuming that low doses of radiation were less harmful and possibly even beneficial was abandoned [8–10] although there are currently no data showing that high dose medical studies have actually increased the incidence of cancer and the full validation of the linear no-threshold model is still lacking in the low dose range (below 100 mSv) [7]. In particular, the evidence gaps are that radiation data gathered from atomic bombings were whole body doses that occurred in a brief period of time, not comparable to small medical doses applied over days or years. Radiation given in fractionated doses as happens with medical testing is probably less harmful than a single dose applied to the same organ. Many of the long-term effects, including cancer, become manifest 20 or more years after the exposure, but diagnostic medical studies are more frequently performed in elderly patients with co-morbidities, less likely to live long enough to develop a radiation-induced illness [7].

In spite of these evidence gaps, in 2005 cardiology imaging guidelines accepted in principle that the risk-benefit assessment balance should include long-term cancer risks on the risk side [11]. In 2005, the interventional cardiology guidelines of the American College of Cardiology Foundation emphasized that "the responsibility of all physicians is to minimize the radiation injury hazard to their patients, to their professional staff and to themselves" [12]. In 2009, the AHA Science Advisory at last delivered the reference doses of common cardiology examinations [13], and in 2010 the ACC committee also overtly expressed the need for appropriate and optimized use of radiation techniques in cardiology [14]. It is now generally recognized that all physicians make every effort to see that "each patient should get the right imaging exam, at the right time, with the right radiation dose", as suggested by the FDA in the 2010 initiative to reduce unnecessary radiation exposure from medical imaging [15]. Attention to radiation protection is one aspect - and not the least important -- of good practice of medicine, and in particular cardiology.

ICRP introduced the quantity effective dose (mSv) for occupational exposures but it is more and more used in medicine as an approach to estimate radiological risk [9]. ICRP recognizes that effective doses can be of value for comparing the relative dose from different diagnostic procedures and for comparing the use of similar technologies and procedures, provided that the referent patient populations are similar with regard to age and sex [9]. Medical radiation from x-rays and nuclear medicine is the largest manmade source of radiation exposure in western countries, accounting for a mean effective dose of 3.0 mSv per head per year, equivalent to the radiological risk of 150 chest x-rays (Figure 1) [16]. Of these, one-fourth come from nuclear medicine (γ-rays) and the remaining from radiology (x-rays). Of the 150 chest x-rays from medical radiation except radiotherapy, almost one-half come from cardiology procedures. In particular, nuclear cardiology accounts for 57% of all nuclear medicine procedures and 85% of the entire cumulative effective dose due to nuclear medicine, whereas cardiac radiology accounts for about 30% of the exposure due to x-ray procedures (Figure 2) [17]. Exact figures can depend upon the specific country, the radiological year, and uncertainties in allocating to a specific subspecialty some examinations, such as chest CT. For instance, in Germany nuclear cardiology accounted for 40% of the overall collective dose from nuclear medicine in the years 1996-2000 [18] and cardiovascular radiology for around 50% of x-rays dose in the radiological year 2005 [19]. Overall there is little doubt that cardiology makes a dominant contribution to global radiological warming. The reasons are simple: 1) cardiology imaging examinations are very common, with about 1 million PCI, 10 million MPI's and 10 million MDCT's per year in the US alone; 2) each procedure involves a very large radiation exposure, which may range from 5 to 57 mSv and more, around an average reference dose of 10-15 mSv for a percutaneous coronary intervention, a cardiac radiofrequency ablation, a multi-detector coronary angiography or a myocardial perfusion imaging scintigraphy [13, 20–22]. In particular, effective doses of invasive cardiology procedures vary widely by a factor of 10 (Table 1), with more complex procedures such as dilation of chronic total coronary occlusion [23] or transthoracic aortic valve replacement [24] or endovascular thoraco-abdominal aneurysm repair [25] which may easily exceed the effective dose of 100 mSv. In addition, interventional cardiologists have an exposure per head per year two to three times higher than that of radiologists and their exposure has increased steadily in the past 5 years [26, 27]. The most active and experienced of interventional cardiologists in high volume catheterization laboratories have an annual exposure equivalent to around 5 mSv per year, and a professional lifetime attributable excess cancer risk of 1 in 100 [8, 28]. For both patients and doctors, the risk is cumulative, meaning that when several test or procedures are performed, dose is added to dose and risk to risk. The cumulative exposure per patient [17, 29, 30] per problem [31], during a single admission [32] may well reach values around a cumulative exposure of 100 mSv.

Medical and natural sources of radiation. Modified from Picano E, BMJ, 2004, ref. 2 updated with Mettler et al, Health Physics, 2009, ref. 16. The effective dose of 1 mSv is equivalent to 50 chest x-rays.

Full size image

The relative contribution of cardiovascular examinations to overall exposure from nuclear medicine (left panel) referred to radiological years 2006. The nuclear cardiology contribution of about 32 chest x-rays per year is matched by the 33 chest x-rays per year from cardiac radiology, for a grand total of 65 chest x-rays, corresponding to 43% of the total exposure of the average US citizen. Redrawn and adapted from ref 16 and 17.

Full size image

A ccording to current risk estimates if 100 subjects are exposed to 100 mSv, 42 will have a spontaneous cancer (independently of radiation exposure) and 1 will have a radiation-induced cancer (with a range of uncertainty of 1 in 30-1 in 300): Figure 3 [8]. This is an average risk, assuming a sex and age distribution similar to that of the entire US population [8]. For any given dose, the risk is 3-4 times higher in children than in adults, 50% lower in an 80-year old compared to a 50-year old subject, and 38% higher in females than in males. These estimates do have a considerable margin of uncertainty, with a 2 to 3 confidence intervals [8].

The risk model of Biological Effects of Ionising Radiation Committee VII for exposure to low-level radiation predicts that about one (red star) out of 100 people would likely develop solid cancer or leukemia from a single exposure of 100 mSv above background. About 42 additional people (yellow circles) in the same group would be expected to develop solid cancer or leukemia from other causes in a lifetime. Roughly half of these cancers would result in death. Modified and adapted from Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation; Nuclear and Radiation Studies Board, Division on Earth and Life Studies, National Research Council of the National Academies. Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press; 2006 (ref. [8]

Full size image

Dose optimization is essential to minimize both the patient's and doctor's risk in the catheterization laboratory [33]. Decreasing patient dose will result in a proportional decrease in scatter dose to the operator [34]. Therefore, techniques that reduce patient dose will generally also reduce the occupational dose [35]. This is a "win-win" situation: the doctor and the patient both benefit (Table 2). Protective shielding is also essential for operator protection. It includes structural (architectural wall) shielding, mobile shielding (with ceiling suspended leaded plastic and table-suspended drapes) and personal shielding (with lead aprons, thyroid collars and leaded glasses). However, the most effective shielding is the operator's knowledge of radiation risk [36] - which is often suboptimal [37–39].

There are two main biological effects of radiation: stochastic effects, which include carcinogenetic and genetic effects, and tissue reactions (previously called deterministic effects), which cause an immediate and very predictable change to the tissue [40]. Tissue reactions happen when the dose exceeds a specific threshold. The two most frequent examples of tissue reactions (deterministic effects) of cardiological interest are cataract formation (in doctors) and skin injury (in patients).

Cataract, or opacification of the lens, is often associated with visual impairment and may be classified into three main categories: nuclear, cortical, and posterior subcapsular, according to their anatomic location [41]. Of the three major categories of age-related cataracts, posterior subcapsular is the least common but it is the one most frequently associated with ionizing radiation exposure. Because of their location along the lens' visual axis, relatively minor posterior subcapsular cataracts can have great impact on vision. The estimated eye dose is around 0.5 mGy/procedure, in cardiac catheterization laboratories when no eye protection is used. Until recently, the dose threshold for radiation-induced lens opacities were considered 2 Gy for a single dose or 5 Gy for fractionated dose [19]. However, several epidemiological studies among Chernobyl clean-up workers, A-bomb survivors, astronauts, residents of contaminated buildings, and surveys of staff in interventional rooms indicate that there is an increased incidence of lens opacities at doses below 0.5 Gy and even suggests a stochastic hypothesis (non-threshold effect) [42]. Whether deterministic or stochastic in nature, lens opacities have been documented in up to 50% of interventional cardiologists [43]. The reasons for this high prevalence are three fold: first is that operator's eyes are exposed to scattered x-rays; second (avoidable) is the frequent failure of some cardiologists to use protective leaded eyewear [43]; and probably third, that the permitted occupational dose limits were too high even to provoke a mental alert. On April 21, 2011, ICRP slashed the earlier dose limit of 150 mSv in a year for the lens of the eye to the present 20 mSv in a year, averaged over a defined period of five years, with no single year exceeding 50 mSv [44].

When fluoroscopic procedures require more than 20 minutes using high-contrast fluoroscopy mode or 60 minutes in low level fluoroscopy, there may be a possibility of patient skin injuries. Significantly, injuries are not limited solely to the use of older equipment, but can occur when poor technique is employed with newer and digital equipment capable of delivering higher doses [45]. Radiation burns remain asymptomatic and often go unrecognized [46]. This is quite contrary to the familiar thermal burn, which is associated with a recognizable source of heat and instantaneous pain. They usually occur on the patient's back (where the x-rays are delivered) and since they develop several weeks after the procedure their association with cardiac interventions may not be considered, and many severe cases come to light through litigation. A case is filed in US courts every 4-5 weeks by patients who have suffered such injuries [47]. In almost every country around the world, reporting significant radiological incidents and accidents that occur during, or as a direct result of using ionizing radiation for a medical procedure is a legal requirement. But in practice, such reporting hardly ever occurs. Very few countries have a functioning reporting system because no one wants to be blamed for patients' radiation related burns, hair loss or skin injury. However, this information is essential if lessons are to be learned. The IAEA has set up its own international reporting system called SAFRAD (SAFety in RADiological procedures). Because the SAFRAD system is anonymous and the IAEA will not supply identifiable data to governmental authorities or other third parties, there will be no fear of blame [48].

We should make every effort to bring the cardiology community from an evidence-poor to an evidence-rich environment in the specific field of radioprotection in cardiology (Table 3). Further data are needed, especially in the low dose range (<100 mSv). BEIR VII listed among top-research needs "future medical imaging studies", including studies of infants who undergo diagnostic exposures [8]. Theoretically, such studies will be a tough challenge, since the extra risk of dying from a single CT scan exposure is estimated to be 1 in 1000, and about 40% of the population eventually have some kind of cancer and 20% of the population will die from it. It has been calculated that an epidemiological study of 5 million people would be required to quantify directly the risk of cancer from exposure of 10 mSv or less [49]. Since the relation linking the required sample size and the exposure dose is hyperbolic, a substantially lower sample size is required if a cumulative diagnostic exposure (of all ionizing tests) is considered (now easily in the range of 100 mSv), if a pediatric or young population is evaluated (in whom fourfold higher effects than an adult are expected for the same radiation dose), and if genetically vulnerable populations are studied (in whom 2 to 3 times the effects of a given dose can be observed in comparison with a genetically resistant population) [50]. Data mining on this very relevant issue has already begun, and in a population of 82,861 patients admitted with acute myocardial infarction, there was a 3% increase in cancer over a mean follow-up of 5 years for every 10 mSv of low-dose ionizing radiation [51]. Another BEIR research need of interest to cardiologists regards "future occupational radiation studies", which can certainly include highly exposed (in the last 2 to 3 decades) interventional cardiologists, a population well suited to assess effects of long-term, low-level radiation exposure in humans [36].

A suggested alternative to the epidemiological approach is the biodosimetry approach, applicable to both cardiological patients and professionally exposed cardiologists [4]. The most suitable biodosimeter for cancer is the assay of double-stranded DNA breaks, micronuclei or chromosome aberrations in circulating peripheral lymphocytes, or gamma-H2AX foci for single-stranded DNA damage. In this way, it is easier to "see" in a more tangible way the direct effects of radiation exposure on proximal markers of cancer, which are intermediate end-points and long-term predictors of disease [52, 53]. In fact, an acute diagnostic or therapeutic x-ray exposure in the 10- to 50 mSv range - well below the threshold of epidemiological evidence linking radiation to cancer - is associated with a 15% increase in micronuclei in adults after invasive cardiovascular interventions [54], a 100% long-term increase in children treated for congenital heart disease 15 to 20 years after the exposure [55] and a 50% increase in interventional cardiologists after 10 to 20 years of catheterization laboratory exposure with cumulative professional dose in the 30 to 100 mSv range [56]. Chronically exposed interventional cardiologists also show altered redox balance and increased susceptibility to apoptotic induction in lymphocytes [57]. A clear recommendation of UNSCEAR 2009 is to pay more attention "to other non-cancer disease entities, in addition to circulatory diseases", encouraging "future epidemiological studies designed to assess clinical and subclinical endpoints, as well as biomarkers, since this information is more likely to lead to insights" [10]. The challenging field ahead is to translate, for both patients and professionally exposed doctors, the generic population risk obtained from epidemiological age-and gender-based risk into a personalized risk [40]. Several genetic, environmental and dietary variables can affect the variability of damage observed to any given level of radiation, and current research is targeted at shifting epidemiology estimates to personalized measures of DNA and chromosomal damage, focused on identifying inter-individual differences that could modulate radiation risks in order to obtain better estimates of the extent of damage. For instance, radiation-associated chromosomal damage in interventional cardiologists is amplified by smoking and by genetic polymorphism of genes involved in DNA repair [58]. If the risk is personalized, it will be easier to implement targeted predictive and chemo-preventive strategies [59], since it is now proven that a variety of biological response modifiers can modulate tissue reactions in many tissues. These include antioxidants, radical scavengers, anti-inflammatory drugs, angiotensin converting enzyme inhibitors, growth factors and cytokines (Figure 4). In many cases these give dose modifying factors of 1.1 to 2, indicating the potential for increasing threshold doses in known exposure cases. In contrast, there are agents which enhance radiation responses, notably other cytotoxic agents such as antimetabolites, alkylating agents, antiangiogenic drugs, and antibiotics, as well as genetic and comorbidity factors [40].

The population risk is in reality due to the average of a spectrum of risks, with higher risks being for instance associated with mutation of genes involved in DNA repair and with the presence of other environmental mutagens such as smoking.

Full size image

Other important cardiology-based lines of research will be technological advancement to reduce the effective dose in different fields, from nuclear cardiology to CT, from interventional cardiology to cardiac radiofrequency ablation (Figure 5). For instance, the recent emphasis on radiation exposure due to CT scanning has engendered a competitive effort on the part of manufacturers (the commercial "dose war", after the "slice war") to reduce the dose while still providing diagnostic images. As a result, cardiac CT angiography can now be performed with high-quality images with a mean effective radiation dose of less than 1 or 2 mSv [60]. Substantial dose reduction can also be achieved in nuclear myocardial perfusion imaging abandoning Thallium (25 mSv+) for Sestamibi (10 mSv), by new reconstruction algorithms, stress-only protocols, and by implementing semiconductor detectors into latest- generation gamma cameras allowing massive scan shortening or dose reduction [22]. Research is currently addressing the issue of finding a way to improve the unacceptably high rate of inappropriate cardiac imaging testing [61], still around 30% for most common ionizing examinations such as myocardial perfusion scintigraphy or cardiac CT [62, 63]. Last but not least, substantial effort will be directed to increasing the currently suboptimal radiological awareness of cardiologists, prescribing doctors and patients, since awareness is the best shield from unnecessary medical radiation exposure. Both FDA [15] and the President's Cancer Panel [64] recommend social communication to patients and doctors. The pattern of this communication might be modelled on the "Image Gently and Step Lightly Campaign", which in the US addressed the issue of radiological responsibility, focusing on the risks of unnecessary and excessive medical radiation from interventional radiology administered to our pediatric patients [65]. User-friendly informatic support or mobile platforms might be helpful for this purpose [66]. Another highly effective, and possibly the best, way to improve the radiological awareness within the cardiology community is to involve cardiologists in a proactive role on studies evaluating the health effects of radiation on themselves. The Multispecialty Occupational Health Group (MOHG) undertook a cohort mortality study comparing cancer and other serious disease outcomes (including cardiovascular diseases and cataracts) in 44,000 physicians performing fluoroscopically guided procedures (including interventional cardiologists, radiologists, neuroradiologists and others) and in 12,000 non-interventional radiologists with risks in 101,000 physicians who are unlikely to be occupationally exposed to radiation (e.g., family physicians or psychiatrists) [67]. Member organizations of the MSOHG include the Society of Cardiac Angiography and Intervention, Society of Interventional Radiology, Heart Rhythm Society, American College of Radiology, American College of Cardiology, Society of Neurointervention Surgery, American Association of Physicists in Medicine, and Society of Invasive Cardiac Professionals. The MSOHG is collaborating with experts in occupational health, epidemiology, and radiation effects from the United States Navy and the Radiation Epidemiology Branch of the National Cancer Institute, to perform epidemiological studies addressing the fundamental questions important to all those working in such an environment.

The radiological dose-sparing cascade provided by technical and cultural upgrading in four critical areas of cardiology: Myocardial Perfusion Imaging (MPI, from thallium to sestamibi tracers, from standard to triple-headed gamma camera, and from gamma camera to PET imaging with N-13 ammonia), MDCT (Multi-Detector Computed Tomography, from retrospective to prospective triggered techniques with dose modulation), interventional cardiology (with 90% dose reduction simply achieved through radioprotection training) and cardiac radiofrequency ablation (moving from standard fluoroscopy to near-zero exposure with non-fluoroscopy navigation techniques).

Full size image

In Italy, the Healthy Cath Lab study is organized by the Italian National Research Council with endorsement of Italian Society of Invasive Cardiologists, and is designed by interventional cardiologists on interventional cardiologists and for interventional cardiologists (http://www.gise.it.healthycathlab). The Italian study population will consist of 500 exposed (high, medium, and low exposure) interventional cardiologists and staff (technicians and staff) and 500 unexposed controls (clinical cardiologists and nurses). With this limited sample size, the detection of potentially increased health risks remains difficult through the epidemiological approach. Therefore, as an alternative to the epidemiological approach the Healthy Cath Lab study will assess non-cancer health effects through "early warning signs", which evaluate initial damage through surrogate endpoints which are easy to measure, non-invasive, and are able to identify long-term risk for subsequent clinically overt disease, such as micronuclei as a surrogate for cancer, telomere length for atherosclerosis and aging, and so on [53].

Cardiologists have to rely on the best available estimates of risk, and at present such evidence is represented by the linear-no-threshold model presented by BEIR VII [8]. Other organizations are basically supportive of this model, including the International Commission on Radiological Protection (2007) [9, 40], United Nations Scientific Committee on the Effects of Atomic Radiation (2008) [10], National US Council of Radiation Protection and Measurements (2001) [68] and UK National Radiological Protection Board (1995) [69]. Other organizations such as the Health Physics Society believe (2004) that LNT is an oversimplification and risk estimates should not be used at < 50 mSv [70]. The French Academy of Sciences (2004) and American Nuclear Society (2001) hold that LNT overestimates risk [71, 72].

It is our opinion that physicians cannot enter into the radiobiological dispute and should simply accept and apply in their daily practice the LNT model and BEIR risk estimates which are incorporated into law in many countries. The BEIR VII risk models were developed based on a comprehensive review of the world literature on radiation epidemiology, and extensive efforts were made to compose a highly expert committee and avoid conflicts of interest. The conclusion is that the LNT best fits the data and should remain the standard for radiation protection although still suffering from substantial indetermination in the low dose range (Figure 6). The risk of cancer also evaluated by BEIR VII (or ICRP) needs to be weighed against the potential benefits of any radiation-based diagnostic or therapeutic procedure [73]. In addition, the lively debate on the existence of a threshold < 50-100 mSv is de facto outdated by the high levels of dose exposure in contemporary patients, who easily cross the threshold in one episode of care, or with a single exam [29–32]. A more substantial uncertainty relates to the entity of cancer risk for any given dose, since both BEIR VII and ICRP apply a reduced estimate of cancer risk based on risk coefficients derived from the Japanese atomic bomb survivors, that is, from persons with acute, high-dose exposures. Such acute, high dose estimates are then combined with a "dose and dose-rate effectiveness factor" (DDREF). Values for this correction factor have mainly been deduced from experiments with laboratory animals and from radiobiological measurements. Specifically, the ICRP-derived estimates of the excess cancer risk after low-dose exposures and after exposures with higher doses but low-dose rates by reducing the corresponding risk value for the atomic bomb survivors by a DDREF of 2.0 [9]. The BEIR VII Committee of the US National Research Council used a DDERF of 1.5 [8]. In the last 10 years, 12 epidemiological studies on cancer after low-dose rate, moderate-dose exposures were included in the analysis of cancer risk related to such exposures [74], and the excess relative risk per dose values were greater than those published by BEIR VII and ICRP. In addition, the possibility of non-cancer health effects currently not accepted in the radioprotection regulating framework are considered increasingly likely, for instance for atherosclerotic effects, proven on epidemiological grounds for doses higher than 500 mSv [40]. According to ICRP, a dose of 500 mSv may lead to approximately 1% of exposed individuals developing cardiovascular or cerebrovascular disease, more than 10 years after the exposure, in addition to the 30-50% suffering from disease independently of the exposure [40]. Cardiologists, researchers and scientific societies should make every effort to move from the current evidence-poor to an evidence-rich milieu, with data directly linking radiation exposure to cancer and non-cancer effects in our patients and in ourselves as exposed population. In the meantime, the adoption of BEIR VII or ICRP estimates - a prudent trade-off between scientific evidence and judgement, and therefore more likely to fall on the conservative side of risk estimate -- is recommended.

The dose-effect relationship between radiation exposure and cancer. The solid line indicates the epidemiological evidence, which is conclusive for doses above 50 to 100 mSv. The dashed line indicates the dose range with absent or inconclusive evidence.

Full size image

In the recent past, sometimes cardiologists have been unaware of the radiological dose of the examination they prescribe or practice, but they should make every effort to reduce unnecessary radiation exposure from medical imaging. This is best obtained through a systematic implementation of the 3A's strategy proposed by the International Atomic Energy Agency in 2011: Audit (of true delivered dose); Appropriateness (since at least one-third of examinations are inappropriate); Awareness (since the knowledge of doses and risks is still largely suboptimal in doctors and patients) [75]. It can be repeated for imaging and invasive cardiologists what has been recently written of radiologists: "they must walk a digital tightrope strung between too much and too little radiation. they must image gently, but not too gently - striking a balance between patient risk and diagnostic value" [76]. The recognition of risks inherent in the use of a known carcinogen such as radiation also opens unprecedented new opportunities for scientific [77], social, technological, bioethics [78, 79] and medical advancement, of interest to scientists, clinical cardiologists, patients, and industry [80]. A good cardiologist - and even more so, a good imaging or interventional cardiologist - cannot be afraid of radiation, but must be very afraid of radiation unawareness.

This work has received financial support from the Istituto Toscana Tumori - progetto SUIT-Heart (stop Useless Imaging Testing in Heart Disease).

Affiliations

1. CNR, Institute of Clinical Physiology, Pisa, Italy

   • Eugenio Picano
   •  & Eliseo Vano

2. San Carlos University Hospital, Complutense University of Madrid, Madrid, Spain

   • Eliseo Vano

Corresponding author

Correspondence to Eugenio Picano.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

EP drafted the manuscript. EV critically reviewed it, and also wrote parts related to dosimetry. All authors read and approved the final manuscript.

Below are the links to the authors’ original submitted files for images.

Reprints and Permissions